IDEAYA Biosciences, Inc. Logo

IDEAYA Biosciences, Inc.

Clinical-stage firm developing precision cancer therapies via synthetic lethality.

IDYA | US

Overview

Corporate Details

ISIN(s):
US45166A1025
LEI:
Country:
United States of America
Address:
5000 SHORELINE CT, SUITE 300, 94080 SOUTH SAN FRANCISCO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapeutics for cancer patients. The company specializes in an approach called synthetic lethality, an emerging class of precision medicine that targets cancer cells by exploiting their specific genetic vulnerabilities. IDEAYA utilizes molecular diagnostics to identify and select patient populations for its potential first-in-class or best-in-class therapies. Its integrated capabilities cover the full development spectrum, from target and biomarker discovery to clinical trials, employing small molecule and protein degrader therapeutic platforms to address unmet needs in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IDEAYA Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IDEAYA Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IDEAYA Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.